Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/14/2026

Hydroxyzine and QT Prolongation: Risks and Management

Contraindications and High-Risk Factors

  • The European Society of Cardiology recommends avoiding hydroxyzine in patients with a history of ventricular arrhythmias, including Torsades de Pointes, due to the risk of QT prolongation 1, 2
  • The European Heart Journal suggests that female sex, age >65 years, uncorrected hypokalemia or hypomagnesemia, and concurrent use of other QT-prolonging medications exponentially increase the risk of QT prolongation and Torsades de Pointes 1, 2
  • The European Heart Journal recommends checking electrolytes and maintaining potassium >4.5 mEq/L and normalizing magnesium to minimize the risk of QT prolongation 1, 2

Pre-Treatment Assessment and Monitoring

  • The Annals of Oncology recommends obtaining a baseline ECG to measure QTc using Fridericia's formula before initiating hydroxyzine treatment 3
  • The European Heart Journal suggests reviewing all medications and discontinuing other QT-prolonging drugs, including class IA and III antiarrhythmics, certain antipsychotics, and antibiotics, to minimize the risk of QT prolongation 1, 2, 4

Management of Hydroxyzine Overdose

  • The European Heart Journal recommends administering 2g IV magnesium sulfate immediately in cases of Torsades de Pointes, regardless of serum magnesium level 4
  • The European Heart Journal suggests performing immediate defibrillation if hemodynamically unstable and using temporary pacing for recurrent episodes after electrolyte repletion 4

Hydroxyzine Contraindications and Precautions

Introduction to Contraindications

  • The American College of Cardiology and other guideline societies recommend that hydroxyzine is contraindicated in patients with a prolonged QT interval, as it can increase the risk of torsades de pointes 5

Alternatives to Hydroxyzine

  • For anxiety, benzodiazepines like lorazepam are safe alternatives to hydroxyzine, as they do not prolong the QT interval, according to Praxis Medical Insights 5
  • For nausea and vomiting, non-pharmacologic approaches or careful electrolyte management should be prioritized, as most antiemetics also prolong QTc, as noted in Praxis Medical Insights 6

Risk Factors for QT Prolongation

  • The American Heart Association, as published in Circulation, identifies risk factors for QT prolongation, including female sex, age >65 years, hypokalemia, hypomagnesemia, bradycardia, and heart failure 7
  • Congenital long QT syndrome or family history of long QT syndrome is a critical risk factor that makes QT prolongation worse, as noted in Praxis Medical Insights 6

Definition of Prolonged QTc

  • A QTc ≥500 ms is universally considered high-risk and represents an absolute contraindication to hydroxyzine, according to the Journal of the American College of Cardiology and Circulation 7, 8

Hydroxyzine‑Induced QT Prolongation and Management

Contraindications and Thresholds

  • Baseline QTc ≥ 500 ms is an absolute contraindication to hydroxyzine therapy; patients with this ECG finding should not receive the drug. (American College of Cardiology) 9
  • Hydroxyzine must be stopped immediately if any follow‑up ECG shows QTc ≥ 500 ms, regardless of dose or duration. (American College of Cardiology) 9

High‑Risk Clinical Factors

  • Serum potassium < 4.5 mmol/L or magnesium < 0.7 mmol/L markedly increases the risk of torsades de pointes when hydroxyzine is used. (American College of Cardiology) 9
  • Concurrent use of other QT‑prolonging agents (e.g., Class IA/III antiarrhythmics, certain antipsychotics, antidepressants, macrolide antibiotics, ondansetron, methadone) exponentially raises the likelihood of hydroxyzine‑related torsades de pointes. (American College of Cardiology) 9

Mandatory Pre‑Treatment Assessment

  • Obtain a baseline 12‑lead ECG and calculate QTc with Fridericia’s formula before initiating hydroxyzine. (American College of Cardiology) 9
  • Correct electrolytes: ensure potassium is ≥ 4.5 mmol/L and magnesium is within the normal range prior to the first dose. (American College of Cardiology) 9
  • Medication review: discontinue any other QT‑prolonging drugs whenever feasible before starting hydroxyzine. (American College of Cardiology) 9

Emergency Management of Hydroxyzine‑Induced Torsades de Pointes

  • Administer 2 g IV magnesium sulfate immediately, irrespective of the patient’s serum magnesium level. (European Society of Cardiology) 10
  • Urgently replete potassium to achieve serum levels > 4.5 mmol/L. (European Society of Cardiology) 10
  • Consider temporary over‑drive pacing or isoproterenol infusion (target heart rate > 90 bpm) for recurrent torsades after electrolyte correction. (European Society of Cardiology) 10

Monitoring and Discontinuation Criteria

  • Repeat ECG 7 days after initiation or after any dose change to reassess QTc. (American College of Cardiology) 9
  • Discontinue hydroxyzine if QTc prolongs by > 60 ms from baseline or if ventricular ectopy or arrhythmic symptoms develop. (American College of Cardiology) 9

REFERENCES

5

Lorazepam Safety in Patients with Prolonged QT Interval [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

6

Safe Antiemetics in Patients with QT Interval Prolongation [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026